Acadia Pharma (ACAD) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $26.41 --0%
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.45), $0.07 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $17 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
